Is Shionogi & Co., Ltd. (SGIOY) a Buy, Sell, or Hold?
OTC : SGIOY
Shionogi & Co., Ltd.
$8.9 USD
$0.03 (0.34%)
- Volume
- 1.24K
- Average Volume
- 146.12K
- Market Capitalization
- $15.15B
- P/E Ratio
- 9.08
- Dividend Yield
- 2.53%
- Price Target
- Year High
- $12.00
- Year Low
- $7.65
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.23
- Current Ratio
- $1.14
Company Overview
OTC
Isao Teshirogi
Drug Manufacturers - Specialty & Generic
Healthcare
SGIOY
6223
JP
USD
Liquidity Metrics
0.39
1.14
1.00
0.37
0.23
Sales & Valuation
$529.81B
4.25
1.35
11.89
118.15
Profitability
$127.83
$217.53B
46.79%
47.29%
16.46%
9.92%
P/E Metrics
9.08
0.19
0.19
Analyst Price Target & Rating
4/5
0 Analysts
%
Financial Health Scores
3.00
3/9
$111.48B
$2.64T
$876.47B
$216.91B
Key Metrics (TTM)
$2.78T
4.93
9.86
1.14
16.46%
6.53%
11.02%
8.41%
$3809.14
374 days
Company Executives
| Name | Title |
|---|---|
| Takeshi Shiota | Corporate Officer and Senior Vice President of Corporate Quality Assurance, Ethics & Compliance Management Div. |
| Toshinobu Iwasaki | Senior Executive Officer & Senior Vice President of Healthcare Business Supervisory Unit |
| Takuji Fujiwara | Accounting & Finance Manager |
| Yoshihiro Furuya | Vice President of General Marketing and Compliance Officer of Corporate GXP Compliance Office |
| Masashi Deguchi | Corporate Officer & Senior Vice President of Sustainability Management Division |
| Kazuhiro Hatanaka | Senior Executive Officer & Senior Vice President of Corporate Supervisory Unit |
| Yoshimasa Kyokawa | Vice President of Corporate Communications & Secretary Office |
| John Apeler Keller | Senior Executive Officer, SVice President of R&D Supervisory Unit and Pharma. Tech. Research Div. & Director |
| Akira Kato | Senior Executive Officer and Senior Vice President of Supply Supervisory Unit |
| Isao Teshirogi | Chief Executive Officer, President & Representative Director |
Poll Results
No votes yet today — be the first to share your view!
About Shionogi & Co., Ltd. (OTC:SGIOY) Stock
Shionogi & Co., Ltd. operates as a Japanese pharmaceutical enterprise, dedicated to the discovery, creation, manufacturing, and commercialization of a diverse array of medicines, diagnostic reagents, and medical equipment within Japan. The firm markets several key therapeutic agents, including Fetroja, a crucial therapy for multi-drug resistant gram-negative bacterial infections; Xofluza, an antiviral medication for influenza; and Tivicay, an effective anti-HIV agent. Shionogi also maintains an extensive research and development pipeline, with numerous compounds under investigation for various conditions. Its development portfolio includes treatments for opioid-induced constipation (Symproic), various pain types such as inflammatory pain (S-120083), neuropathic pain (S-010887, sivopixant), ... and neuropathic low back pain (S-637880). Sivopixant is additionally being explored for sleep apnea syndrome and refractory/unexplained chronic cough. In neuroscience, the company is advancing S-117957 for insomnia, Zuranolone for depression, SDT-001 for attention-deficit/hyperactivity disorder, and BPN14770 for Fragile X syndrome and Alzheimer's disease. Furthermore, it is developing S-237648 and S-309309 as potential obesity treatments. In oncology and hepatology, ADR-001 addresses decompensated liver cirrhosis, and S-723595 targets NASH. Multiple anti-cancer compounds are in development, including S-588410 for esophageal and bladder cancer, S-488210 for head and neck squamous cell carcinoma, S-588210 and S-531011 for solid tumors, and S-222611 for malignant tumors. Other experimental therapies include S-770108 for idiopathic pulmonary fibrosis, SR-0379 for cutaneous ulcers, S-005151 for stroke and epidermolysis bullosa, and S-0373 for spinocerebellar ataxia. Addressing the ongoing pandemic, Shionogi is also advancing S-600918 and S-217622 for COVID-19, with S-555739 specifically aimed at preventing the aggravation of the disease. Beyond therapeutics, it supplies antibody test kits for COVID-19. The organization has established collaborative agreements with institutions like Nagasaki University, the National Institute of Infectious Diseases, and The Kitasato University to further the development of antimalarial drugs. Founded in 1878, the company was initially known as Shionogi Shoten Co., Ltd. before adopting its current designation, Shionogi & Co., Ltd., in 1943. Its corporate operations are based in Osaka, Japan.
Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) Beats Q1 Earnings Estimates
2026-08-03 08:11:08
Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of $0.18 per share.
2026-07-20 11:01:17
Shionogi & Co. (SGIOY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2026-05-13 17:08:00
OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, PhD; hereinafter “Shionogi”) announced that results from its global, double-blind, randomized, placebo-controlled Phase 3 study, SCORPIO-PEP, were published in the New England Journal of Medicine. A five-day course of ensitrelvir significantly reduced the risk of symptomatic COVID-19 by 67% in individuals following exposure to an infected individual through Day 10 compare.
Frequently Asked Questions
-
What is the current Shionogi & Co., Ltd. (SGIOY) stock price?
-
Shionogi & Co., Ltd.(OTC:SGIOY) stock price is $8.9 in the last trading session. During the trading session, SGIOY stock reached the peak price of $12 while $7.65 was the lowest point it dropped to. The percentage change in SGIOY stock occurred in the recent session was 0.34% while the dollar amount for the price change in SGIOY stock was $0.03.
-
SGIOY's industry and sector of operation?
-
The OTC listed SGIOY is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.
-
Who are the executives of SGIOY?
-
Takeshi Shiota | Corporate Officer and Senior Vice President of Corporate Quality Assurance, Ethics & Compliance Management Div.
Toshinobu Iwasaki | Senior Executive Officer & Senior Vice President of Healthcare Business Supervisory Unit
Takuji Fujiwara | Accounting & Finance Manager
Yoshihiro Furuya | Vice President of General Marketing and Compliance Officer of Corporate GXP Compliance Office
Masashi Deguchi | Corporate Officer & Senior Vice President of Sustainability Management Division -
How many employees does SGIOY have?
-
Number of SGIOY employees currently stands at 6223. SGIOY operates from 1-8, Doshomachi 3-chome, Osaka, OS 530-0011, JP.
-
Link for SGIOY official website?
-
Official Website of SGIOY is: https://www.shionogi.com
-
How do I contact SGIOY?
-
SGIOY could be contacted at phone #81 6 6202 2161 and can also be accessed through its website. SGIOY operates from 1-8, Doshomachi 3-chome, Osaka, OS 530-0011, JP.
-
How many shares of SGIOY are traded daily?
-
The average number of SGIOY shares traded daily for last 3 months was 146.12K.
-
What is the market cap of SGIOY currently?
-
The market value of SGIOY currently stands at $15.15B with its latest stock price at $8.9